Across TCGA pan-cancer cohorts, ARL14EPL Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated ARL14EPL data layer compared with 20 for mass-spec protein.
The strongest signal is observed in small cell lung cancer (SCLC), where higher ARL14EPL Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ARL14EPL expression acts as an unfavorable survival marker.
SCLC are the cancer types where ARL14EPL Mutation most reproducibly stratifies survival.